{"id":547,"date":"2021-11-08T17:42:51","date_gmt":"2021-11-08T22:42:51","guid":{"rendered":"https:\/\/angany.com\/?p=547"},"modified":"2021-11-09T18:42:37","modified_gmt":"2021-11-09T23:42:37","slug":"angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide","status":"publish","type":"post","link":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/","title":{"rendered":"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide"},"content":{"rendered":"

Le Food Allergy Center du Massachusetts General Hospital entamera les essais pr\u00e9cliniques du candidat-vaccin d\u2019Angany.<\/b><\/p>\n

 <\/p>\n

QU\u00c9BEC, CANADA, 9 NOV., 2021,<\/span> Angany inc. annonce le d\u00e9but d\u2019un partenariat avec le Dr Wayne Shreffler, MD, PhD, chef de la division d\u2019allergologie et d\u2019immunologie p\u00e9diatrique et directeur du Food Allergy Center du Massachusetts General Hospital et du MassGeneral Hospital for Children, pour une s\u00e9rie approfondie d’\u00e9tudes pr\u00e9cliniques sur le candidat biologique d’Angany BP\/AH-01 contre l’allergie \u00e0 l’arachide. Ces exp\u00e9riences cellulaires humaines ex vivo utiliseront des technologies de pointe en mati\u00e8re de marqueurs cellulaires. L’objectif est d’\u00e9valuer les donn\u00e9es relatives \u00e0 l’\u00e9ventuel profil de s\u00e9curit\u00e9 (hypoallerg\u00e9nicit\u00e9) et de pouvoir immunostimulateur anti-allergique du BP\/AH-01 Ces \u00e9tudes pr\u00e9parent l\u2019entr\u00e9e en phase clinique chez l\u2019humain de son candidat-th\u00e9rapeutique contre l\u2019allergie \u00e0 l\u2019arachide pr\u00e9vue pour 2022.<\/span><\/p>\n

\u00ab\u00a0Nous sommes tr\u00e8s heureux que notre nouvelle approche de l’immunoth\u00e9rapie allerg\u00e9nique ait suscit\u00e9 la collaboration enthousiaste de certaines des \u00e9quipes scientifiques parmi les plus prestigieuses dans le monde et nous nous r\u00e9jouissons de cette opportunit\u00e9 d\u2019innover en mati\u00e8re d\u2019immunoth\u00e9rapie de l\u2019allergie avec le Dr Shreffler et son \u00e9quipe,\u00a0\u00bb<\/span><\/i> mentionne le Dr V\u00e9zina, PDG d\u2019Angany. <\/span>\u00ab\u00a0Cette \u00e9tape importante du programme de d\u00e9veloppement pharmaceutique d’Angany devrait donner un nouvel espoir aux millions de personnes touch\u00e9es par les allergies alimentaires dans le monde.\u00a0\u00bb<\/span><\/i><\/p>\n

En s’appuyant sur la <\/span>e<\/span><\/i>Bioparticle\u2122 et l\u2019approche d\u2019immunomodulation <\/span>e<\/span><\/i>Bioparticle-Potentiated Immunotherapy\u2122 qui lui sont exclusives, Angany a d\u00e9velopp\u00e9 un biologique immunoth\u00e9rapeutique qui vise \u00e0 changer le cours de la maladie chez les personnes affect\u00e9es d’allergie aux arachides.<\/span><\/p>\n

\u00ab\u00a0Notre \u00e9quipe a utilis\u00e9 la biologie synth\u00e9tique pour cr\u00e9er des ultrastructures d’allerg\u00e8nes qui imitent les motifs de surface des virus. Ce faisant, nous avons pu modifier l’interaction entre les allerg\u00e8nes et le syst\u00e8me immunitaire des patients allergiques. Nos \u00e9tudes in vivo animales et ex vivo humaines sugg\u00e8rent que l’immunisation avec des allerg\u00e8nes pr\u00e9sent\u00e9s comme des pseudo-pathog\u00e8nes d\u00e9clenche une forte r\u00e9ponse immunitaire protectrice sp\u00e9cifique de l’allerg\u00e8ne-cible, ceci avec une caract\u00e9ristique d\u2019hypoallerg\u00e9nicit\u00e9 remarquable,\u201d<\/span><\/i> explique le Dr. V\u00e9zina.<\/span><\/p>\n

\u00ab\u00a0Le traitement potentiel de l’allergie \u00e0 l’aide d’un vecteur auto-adjuvant s’appuie sur la forte r\u00e9ponse anticorps connue des IgG sp\u00e9cifiques \u00e0 l’allerg\u00e8ne \u00bb<\/span><\/i>, explique le Dr Shreffler. <\/span>\u00ab\u00a0L’objectif ultime est de trouver de nouveaux et meilleurs moyens d’aider les tr\u00e8s nombreux enfants et adultes dont la vie est affect\u00e9e par l’allergie aux arachides. \u00bb<\/span><\/i><\/p>\n

 <\/p>\n

\u00c0 propos de Angany<\/b><\/p>\n

Angany est une soci\u00e9t\u00e9 pharmaceutique priv\u00e9e franco-canadienne, de stade pr\u00e9clinique avanc\u00e9, qui se consacre \u00e0 la lutte contre l’allergie avec une approche novatrice de l’immunoth\u00e9rapie. Le PDG d’Angany, le Dr Louis-Philippe V\u00e9zina, est un entrepreneur pharmaceutique \u00e0 succ\u00e8s, mondialement reconnu pour son expertise dans la conception et la production de nouvelles g\u00e9n\u00e9rations de vaccins. L’entreprise poursuit une mission initi\u00e9e en France en 2010. Elle pr\u00e9voit entrer en phase clinique de d\u00e9veloppement au courant de l\u2019ann\u00e9e 2022 avec son premier candidat-th\u00e9rapeutique contre l’allergie aux chats. Cette introduction sera suivie de pr\u00e8s par celle du candidat traitement contre l’allergie aux arachides. Angany a d\u00e9velopp\u00e9 une plateforme de production biopharmaceutique v\u00e9g\u00e9tale de 3\u00e8me g\u00e9n\u00e9ration, flexible, rapide et facilement \u00e9volutive. Angany pr\u00e9voit que sa plateforme vaccinale eBioparticle\u2122 trouvera rapidement des applications directes dans d’autres domaines que l’allergie, entre autres dans l’immunoth\u00e9rapie du cancer et dans le traitement des maladies auto-immunes.<\/span><\/p>\n

-30-<\/span><\/p>\n

\u00a0<\/span>Pour plus d’informations, veuillez consulter : <\/span>www.angany.com<\/span><\/a><\/p>\n

 <\/p>\n

CONTACT<\/span><\/p>\n

Guy Tropper<\/b><\/p>\n

Vice-pr\u00e9sident senior, Affaires m\u00e9dicales et d’entreprise<\/span><\/p>\n

guy.tropper@angany.com<\/span><\/p>\n

+1 (450) 521-1181<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Le Food Allergy Center du Massachusetts General Hospital entamera les essais pr\u00e9cliniques du candidat-vaccin d\u2019Angany.   QU\u00c9BEC, CANADA, 9 NOV., 2021, Angany inc. annonce le d\u00e9but d\u2019un partenariat avec le…<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[3],"tags":[],"yoast_head":"\nAngany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide - ANGANY<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide - ANGANY\" \/>\n<meta property=\"og:description\" content=\"Le Food Allergy Center du Massachusetts General Hospital entamera les essais pr\u00e9cliniques du candidat-vaccin d\u2019Angany.   QU\u00c9BEC, CANADA, 9 NOV., 2021, Angany inc. annonce le d\u00e9but d\u2019un partenariat avec le...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/\" \/>\n<meta property=\"og:site_name\" content=\"ANGANY\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/anganygenetics\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-08T22:42:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-09T23:42:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/angany.com\/wp-content\/uploads\/2020\/12\/angany-facebook.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"841\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"casacom\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/\",\"url\":\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/\",\"name\":\"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide - ANGANY\",\"isPartOf\":{\"@id\":\"https:\/\/angany.com\/fr\/#website\"},\"datePublished\":\"2021-11-08T22:42:51+00:00\",\"dateModified\":\"2021-11-09T23:42:37+00:00\",\"author\":{\"@id\":\"https:\/\/angany.com\/fr\/#\/schema\/person\/2c964a8f1857af61c2d3f58a5ad14b0e\"},\"breadcrumb\":{\"@id\":\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/angany.com\/fr\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angany.com\/fr\/#website\",\"url\":\"https:\/\/angany.com\/fr\/\",\"name\":\"ANGANY\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angany.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/angany.com\/fr\/#\/schema\/person\/2c964a8f1857af61c2d3f58a5ad14b0e\",\"name\":\"casacom\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angany.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1f0f70ecf21bbf561669224116e345ce?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1f0f70ecf21bbf561669224116e345ce?s=96&d=mm&r=g\",\"caption\":\"casacom\"},\"url\":\"https:\/\/angany.com\/fr\/author\/casacom\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide - ANGANY","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/","og_locale":"fr_FR","og_type":"article","og_title":"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide - ANGANY","og_description":"Le Food Allergy Center du Massachusetts General Hospital entamera les essais pr\u00e9cliniques du candidat-vaccin d\u2019Angany.   QU\u00c9BEC, CANADA, 9 NOV., 2021, Angany inc. annonce le d\u00e9but d\u2019un partenariat avec le...","og_url":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/","og_site_name":"ANGANY","article_publisher":"https:\/\/www.facebook.com\/anganygenetics\/","article_published_time":"2021-11-08T22:42:51+00:00","article_modified_time":"2021-11-09T23:42:37+00:00","og_image":[{"width":1600,"height":841,"url":"https:\/\/angany.com\/wp-content\/uploads\/2020\/12\/angany-facebook.jpg","type":"image\/jpeg"}],"author":"casacom","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/","url":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/","name":"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide - ANGANY","isPartOf":{"@id":"https:\/\/angany.com\/fr\/#website"},"datePublished":"2021-11-08T22:42:51+00:00","dateModified":"2021-11-09T23:42:37+00:00","author":{"@id":"https:\/\/angany.com\/fr\/#\/schema\/person\/2c964a8f1857af61c2d3f58a5ad14b0e"},"breadcrumb":{"@id":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angany.com\/fr\/angany-annonce-un-candidat-vaccin-pour-le-traitement-de-lallergie-a-larachide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/angany.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Angany annonce un candidat-vaccin pour le traitement de l\u2019allergie \u00e0 l\u2019arachide"}]},{"@type":"WebSite","@id":"https:\/\/angany.com\/fr\/#website","url":"https:\/\/angany.com\/fr\/","name":"ANGANY","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angany.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/angany.com\/fr\/#\/schema\/person\/2c964a8f1857af61c2d3f58a5ad14b0e","name":"casacom","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angany.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1f0f70ecf21bbf561669224116e345ce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1f0f70ecf21bbf561669224116e345ce?s=96&d=mm&r=g","caption":"casacom"},"url":"https:\/\/angany.com\/fr\/author\/casacom\/"}]}},"_links":{"self":[{"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/posts\/547"}],"collection":[{"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/comments?post=547"}],"version-history":[{"count":9,"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/posts\/547\/revisions"}],"predecessor-version":[{"id":563,"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/posts\/547\/revisions\/563"}],"wp:attachment":[{"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/media?parent=547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/categories?post=547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angany.com\/fr\/wp-json\/wp\/v2\/tags?post=547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}